bullish
Sosei Group (4565 JP): Partners’ Pipeline Progress Reflects Power of Drug Discovery Platform
Tina has highlighted this Insight as a Top Pick
352 Views18 Jan 2023 10:30
SUMMARY
- Sosei Group (4565 JP) is currently eligible for total milestone payment of more than $9.5B for its existing collaborations. During 9MFY23, Sosei reported revenue growth of 141% YoY to ¥8.6B.
- Pfizer Inc (PFE US) has dosed first subject in phase 2 clinical trial of type 2 diabetes drug candidate PF-07081532. Achievement of this milestone triggers a $10M payment to Sosei.
- Sosei has four programs in preclinical studies and 10+ in discovery phase, which are still unpartnered. The company has a cash runway into 2025 to fund its drug discovery activities.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Quiddity Leaderboard NIFTY Sep 23: LTIMINDTREE Could Be an Intra-Review NIFTY 50 ADD13 Apr 2023
- TOPIX Inclusions: Who Is Ready (Apr 2023)11 Apr 2023
- Sosei Group (4565 JP) TSE Prime Promotion and TOPIX Inclusion... Finally08 Mar 2023
- Japan Healthcare: Pair Trade Ideas- Long Sosei Group (4565 JP), Short Takara Bio (4974 JP)06 Oct 2022
x